Data / Drug companies / Rising Pharma Holdings, Inc.
Rising Pharma Holdings, Inc.: 189 products in the FDA NDC directory, labeler code 16571
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Rising Pharma Holdings, Inc. (labeler code 16571) lists 189 products in the FDA National Drug Code Directory, covering 85 finished drugs by generic name. By type: 181 prescription drugs, 8 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on October 15, 2026.
The request: Watch Rising Pharma Holdings, Inc. (FDA labeler code 16571): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 16571
- Products in commercial distribution
- 189
- Packages
- 378
- Finished drugs by generic name
- 85
- Prescription products
- 181
- Over the counter products
- 8
- Controlled substance products
- Schedule IV 12
- Flagged as original packager
- 180 of 180 products that carry the flag
- Started marketing in the last 12 months
- 6
- Products with a marketing end date set
- 1
- Earliest marketing start
- September 10, 2004
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 162 | 85.7% |
| Other unapproved drugs | 14 | 7.4% |
| Authorized generics (NDA) | 10 | 5.3% |
| New drug applications (NDA) | 2 | 1.1% |
| Over the counter monograph drugs | 1 | 0.5% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 181 | 95.8% |
| Over the counter drugs | 8 | 4.2% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 77 | 40.7% |
| Tablet, film coated | 37 | 19.6% |
| Capsule | 24 | 12.7% |
| Tablet, extended release | 10 | 5.3% |
| Solution | 9 | 4.8% |
| Capsule, extended release | 7 | 3.7% |
| Tablet, chewable | 4 | 2.1% |
| Tablet, orally disintegrating | 3 | 1.6% |
| Suppository | 3 | 1.6% |
| Tablet, delayed release | 3 | 1.6% |
| Cream | 2 | 1.1% |
| Tablet, film coated, extended release | 2 | 1.1% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Mycophenolate Mofetil | 16571-282 | Powder, for suspension | Generic drugs (ANDA) | October 15, 2026 |
| Aminocaproic Acid | 16571-327 | Tablet | Generic drugs (ANDA) | September 20, 2026 |
| Aminocaproic Acid | 16571-326 | Tablet | Generic drugs (ANDA) | September 20, 2026 |
| Phenoxybenzamine hydrochloride | 16571-874 | Capsule | Generic drugs (ANDA) | August 26, 2026 |
| Clindamycin Phosphate | 16571-256 | Solution | Generic drugs (ANDA) | March 23, 2026 |
| Dichlorphenamide | 16571-242 | Tablet | Generic drugs (ANDA) | November 18, 2025 |
| Sulfasalazine | 16571-261 | Tablet | Generic drugs (ANDA) | November 4, 2025 |
| Sirolimus | 16571-806 | Solution | Generic drugs (ANDA) | July 15, 2025 |
| Dicyclomine hydrochloride | 16571-260 | Capsule | Generic drugs (ANDA) | June 23, 2025 |
| Memantine Hydrochloride | 16571-855 | Capsule, extended release | Generic drugs (ANDA) | June 1, 2025 |
| Memantine Hydrochloride | 16571-854 | Capsule, extended release | Generic drugs (ANDA) | June 1, 2025 |
| Memantine Hydrochloride | 16571-853 | Capsule, extended release | Generic drugs (ANDA) | June 1, 2025 |
| Memantine Hydrochloride | 16571-852 | Capsule, extended release | Generic drugs (ANDA) | June 1, 2025 |
| Olopatadine hydrochloride | 16571-882 | Solution | Generic drugs (ANDA) | May 1, 2025 |
| Olopatadine hydrochloride | 16571-861 | Solution | Generic drugs (ANDA) | May 1, 2025 |
| Mesalamine | 16571-246 | Suppository | Generic drugs (ANDA) | April 14, 2025 |
| Potassium chloride extended release | 16571-843 | Tablet, extended release | Generic drugs (ANDA) | February 13, 2025 |
| Potassium chloride extended release | 16571-842 | Tablet, extended release | Generic drugs (ANDA) | February 13, 2025 |
| Itraconazole | 16571-245 | Capsule | Generic drugs (ANDA) | February 3, 2025 |
| Carbidopa and Levodopa | 16571-159 | Tablet, orally disintegrating | Generic drugs (ANDA) | January 8, 2025 |
| Carbidopa and Levodopa | 16571-158 | Tablet, orally disintegrating | Generic drugs (ANDA) | January 8, 2025 |
| Carbidopa and Levodopa | 16571-157 | Tablet, orally disintegrating | Generic drugs (ANDA) | January 8, 2025 |
| Potassium citrate | 16571-865 | Tablet, extended release | Generic drugs (ANDA) | December 15, 2024 |
| Potassium citrate | 16571-864 | Tablet, extended release | Generic drugs (ANDA) | December 15, 2024 |
| Timolol Maleate | 16571-225 | Tablet | Generic drugs (ANDA) | December 10, 2024 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.